Clinical Translation of 18F-Labeled Hydroxyphenethylguanidines

Completed · Early Phase 1

Conditions studied: Autonomic Peripheral Nervous System Diseases

In brief

The purpose of this study is to perform first-in-human PET imaging studies of two new cardiac sympathetic nerve imaging agents, 4-\[18F\]fluoro-meta-hydroxyphenethylguanidine (\[18F\]4F-MHPG) and 3-\[18F\]fluoro-para-hydroxyphenethylguanidine (\[18F\]3F-PHPG).

Key facts

Study ID

NCT02385877

Run by

University of Michigan

People needed

16

Starts

2015-03-01

Expected to finish

2016-08-01

Last updated by the study team

2017-07-02

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Non-obese (BMI < 30)
• Normal blood pressure
• Normal blood lipid profile
• No history of prior cardiovascular disease
• Not susceptible to claustrophobia
• Ability to lay flat for 90 min

You may not qualify if…

• Obesity (BMI > 30)
• Risk factors for heart disease (age > 55y, hypertension, smoking, high blood pressure, high cholesterol levels, diabetes, etc.)
• History of heart disease (heart attack, atrial fibrillation, ventricular tachycardia, exertional angina)
• Currently using certain medications that may interact with cardiac nerves (antidepressants, cold medications, nasal decongestants, monoamine oxidase inhibitors, etc.)
• Claustrophobia
• Inability to lie flat for 90 min
• Pregnant or breast feeding

Where it is running

• University of Michigan — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.